Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 12.2% in October

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 3,600 shares, a decline of 12.2% from the September 30th total of 4,100 shares. Based on an average daily trading volume, of 23,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company’s stock are short sold.

Kiora Pharmaceuticals Stock Down 2.2 %

NASDAQ KPRX traded down $0.08 during trading on Thursday, reaching $3.62. 11,876 shares of the company’s stock were exchanged, compared to its average volume of 76,325. Kiora Pharmaceuticals has a 1 year low of $3.00 and a 1 year high of $8.98. The company has a 50 day moving average price of $3.55 and a two-hundred day moving average price of $4.36.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its earnings results on Friday, August 9th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.42. The firm had revenue of $0.02 million during the quarter. On average, analysts forecast that Kiora Pharmaceuticals will post 1.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a report on Thursday, August 22nd.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for about 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.